To perform differential chromatin accessibility analysis between mutant and wild-type p53 tumours, we focused on two cancer subtypes, breast infiltrating ductal carcinoma and colon adenocarcinoma, which have sufficient numbers of samples in both groups. This evidence concerns the gene TP53 and neoplasm.